PPBT Purple Biotech Ltd.: Enterprise Value to Sales Volume

The valuation of Purple Biotech (PPBT) currently depends solely on trial results, as the company lacks pricing power. The company's price-to-sales ratio reflects the current trend, while 0.00 determines the latest valuation metric. Growth prospects are based on patents promising global market capture, while robotic AI screening automates the development of new targeted drugs.
Purple Biotech Corp - analytical breakdowns and key metrics (PPBT)

To identify fundamental support for an asset, it is essential to analyze changes in the EV/Sales multiple, which compares the total enterprise value to revenue, excluding the impact of debt to detect market overheating. Given the high clinical risks and constant capital dilution at Purple Biotech (PPBT), this indicator is critical, as it reveals the extent of the gap between the valuation of R&D potential and actual cash flows.